Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
Healthcare
$8.62 +0.12%
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
52W Low $6.36High $18.98
Volume 0.01M
Average 0.02M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$24.01M
FY 2025 · Annual
Investing Cash Flow
-$9.58M
FY 2025 · Annual
Financing Cash Flow
$2.28M
FY 2025 · Annual
-95.7% YoYCash Flow Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 4K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 971.53K | 1.44M | 2.17M | 2.11M | 3.24M |
| Change in Working Capital | (485.64K) | 991K | 369K | (1.03M) | (1.5M) |
| Accounts Receivables | (67.4K) | 267.55K | (323K) | (43K) | 66.14K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (390.47K) | 726.11K | 0 | 0 | 0 |
| Other Working Capital | (27.77K) | (1.93K) | 692K | (982K) | (1.57M) |
| Other Non-Cash Items | 9.82M | 2.91M | (1.07M) | 2.02M | (435.77K) |
| Operating Cash Flow | (5.03M) | (5.78M) | (14.5M) | (24.98M) | (24.01M) |
| Capital Expenditures | (7.25K) | (3K) | (18K) | (6K) | (6.1K) |
| Acquisitions (Net) | 1.75M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (17.52M) | (37.34M) | (23.78M) |
| Sales of Investments | 0 | 0 | 0 | 43.68M | 14.2M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 1.74M | (3K) | (17.54M) | 6.34M | (9.58M) |
| Debt Repayment | 186.57K | 0 | (284K) | 0 | 0 |
| Common Stock Issued | 7.08M | 2.78M | 32.46M | 42.8M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185.46K | 0 | 18.85M | 10.68M | 0 |
| Financing Cash Flow | 7.45M | 2.78M | 51.03M | 53.49M | 2.28M |
| Effect of Forex Changes | (1.44K) | (76K) | 1.15M | 744K | (890.45K) |
| Net Change in Cash | 4.15M | (2.95M) | 20.14M | 35.59M | (32.2M) |
| Free Cash Flow | (5.04M) | (5.79M) | (14.52M) | (24.98M) | (24.02M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$25.3M
+ D&A$4.0K
+ Stock-Based Comp$3.2M
+ Deferred Tax$0
- Working Capital-$1.5M
- Other Non-Cash-$435.8K
= Operating Cash Flow-$24.0M
- Capex-$6.1K
= Free Cash Flow-$24.0M
Analysis
FY2025 free cash flow is -$24.0M. FCF conversion is 94.9% of net income. Operating cash flow was -$24.0M, with capex of -$6.1K. The largest bridge item is Stock-Based Comp at $3.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
No filings found.
Does MSCL.TO generate free cash flow?
Satellos Bioscience Inc. (MSCL.TO) generated -$24.02M of free cash flow in fiscal 2025.
How much operating cash flow does MSCL.TO produce?
Operating cash flow was -$24.01M, before capital expenditures of $6,101.00.
Continue the stock analysis
Jump to another research area for this company.